RNA-mediated therapeutics: From gene inactivation to clinical application

Current Topics in Medicinal Chemistry

Volumn 6, Issue 16, 2006, Pages 1737-1758

  Kalavrizioti, Dimitra ^a   Vourekas, Anastassios ^a   Stamatopoulou, Vassiliki ^a   Toumpeki, Chrisavgi ^a   Giannouli, Stamatina ^b   Stathopoulos, Constantinos ^b   Drainas, Denis ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Antisense; Cancer; Clinical trials; Gene inactivation; Gene therapy; Hairpin; Hammerhead; HIV; M1 RNA; Ribozymes; RNA interference; RNase P; Self splicing introns

Indexed keywords

ABC TRANSPORTER; ADENOVIRUS VECTOR; ANGIOZYME; ANTINEOPLASTIC AGENT; CHOLESTEROL DERIVATIVE; CISPLATIN; CYCLODEXTRIN; DOXORUBICIN; FOMIVIRSEN; HAMMERHEAD RIBOZYME; HEPTAZYME; INTERFERON; K RAS PROTEIN; LAURIC ACID; LENTIVIRUS VECTOR; LIPOSOME; LITHOCHOLIC ACID; MACROGOL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PARVOVIRUS VECTOR; POLYETHYLENEIMINE; POLYMER; RAS PROTEIN; RETROVIRUS VECTOR; RIBONUCLEASE P; RIBOZYME; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE; VIRUS RNA;

ALZHEIMER DISEASE; CATALYSIS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GENE INACTIVATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; INTRON; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOGENESIS IMPERFECTA; RETINITIS PIGMENTOSA; REVIEW; RIBOSOME; RNA INTERFERENCE; RNA SPLICING; RNA TRANSLATION; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE SILENCING; GENE THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA;

EID: 33748320882     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778194253     Document Type: Review

References (300)

1. Zamecnik, P. C.; Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 1978, 75, 280-284.
2. Cousin, J. Breakthrough of the year. Small RNAs make big splash. Science 2002, 298, 2296-2297.
3. Robinson, J. RNAi therapeutics: How likely, how soon? PLoS Biology 2004, 2, 18-20.
4. Forster, A.C.; Symons, R.H. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987, 49, 211-220.
5. Symons, R.H. Plant pathogenic RNAs and RNA catalysis. Nucleic Acids Res. 1997, 25, 2683-2689.
6. Collins, R.F.; Gellatly, D.L.; Sehgal, O.P.; Abouhaidar, M.G. Self-cleaving circular RNA associated with rice yellow mottle virus is the smallest viroid-like RNA. Virology 1998, 241, 269-275.
7. Hutchins, C.J.; Rathjen, P.D.; Forster, A.C.; Symons, R.H. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 1986, 14, 3627-3640.
8. Hernández, C.; Flores, R. Plus and minus RNAs of peach latent mosaic viroid self-cleave in vitro via hammerhead structures. Proc. Natl. Acad. Sci. USA 1992, 89, 3711-3715.
9. Navarro, B.; Flores, R. Chrysanthemum chlorotic mottle viroid: unusual structural properties of a subgroup of self-cleaving viroids with hammerhead ribozymes. Proc. Natl. Acad Sci. USA 1997, 94, 11262-11267.
10. Epstein, L. M.; Gall, J. G. Self-cleaving transcripts of satellite DNA from the newt. Cell 1987, 48, 535-543.
11. Ferbeyre, G.; Smith, J.M.; Cedergren, R. Schistosome satellite DNA encodes active hammerhead ribozymes. Mol. Cell. Biol. 1998, 18, 3880-3888.
12. Rojas, A. A.; Vázquez-Tello, A.; Ferbeyre, G.; Venanzetti, F.; Bachmann, L.; Paquin, B.; Sbordoni, V.; Cedergren, R. Hammerhead-mediated processing of satellite pDo500 family transcripts from Dolichopoda cave crickets. Nucleic Acids Res. 2000, 28, 4037-4043.
13. Branch, A. D.; Robertson, H. D. A replication cycle for viroids and other small infectious RNAs. Science 1984, 223, 450-455.
14. Symons RH. Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem. Sci. 1989, 14, 445-450.
15. 2+ ions in ribozyme reactions. FASEB J. 1993, 7, 137-142.
16. Rujner, D. E.; Stormo, G. D.; Uhlenbeck, O. C. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990, 29, 10695-10702.
17. Uhlenbeck, O. C. A small catalytic oligoribonucleotide. Nature 1987, 328, 596-600.
18. Haseloff, J.; Gerlach, W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988, 334, 585-591.
19. Shimayama, T.; Nishikawa, S.; Taira, K. Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry 1995, 34, 3649-3654.
20. Kore, A.R.; Vaish, N.K.; Kutzke, U., Eckstein, F. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res. 1998, 26, 4116-4120.
21. Buzayan, J. M.; Gerlach, W. L.; Bruening, G. Non-enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA. Nature, 1986, 323, 349-353.
22. Buzayan, J. M.; Hampel, A.; Bruening, G. Nucleotide sequence and newly formed phosphodiester bond of spontaneously ligated satellite tobacco ringspot virus RNA. Nucleic Acids Res. 1986, 14, 9729-9743.
23. Fedor, M. J. Structure and function of the hairpin ribozyme. J. Mol. Biol. 2000, 297, 269-291.
24. Rupert, P.B.; Ferré-D'Amaré, A.R. Crystal structure of a hairpin ribozyme-inhibitor complex with implications for catalysis. Nature 2001, 410, 780-786.
25. Anderson; P.; Monforte, J.; Tritz, R.; Nesbitt, S.; Hearst, J.; Hampel, A. Mutagenesis of the hairpin ribozyme. Nucleic Acids Res. 1994, 22, 1096-1100.
26. Scherer, L. J.; Rossi, J. J. Approaches for the sequence-specific knockdown of mRNA. Nature Biotechnol. 2003, 21, 1457-1465.
27. Nesbitt, S.; Hegg, L.A.; Fedor, M.J. An unusual pH independent and metal-ion-independent mechanism for hairpin ribozyme catalysis. Chem. Biol. 1997, 4, 619-630.
28. Pljevaljcic, G.; Klostermeier, D.; Millar, D. P. The Tertiary Structure of the Hairpin Ribozyme Is Formed through a Slow Conformational Search. Biochemistry 2005, 44, 4870-4876.
29. Mercatanti, A.; Rainaldi, G.; Mariani, L.; Marangoni, R.; Citti, L. A method for prediction of accessibile sites on an mRNA sequense for target selection of hammerhead ribozymes. J. Computat. Biol. 2002, 9, 641-653.
30. Campbell, T. B.; McDonald, C. K.; Hagen, M. The effect of structure in a long target RNA on ribozyme cleavage efficiency. Nucleic Acids Res. 1997, 25, 4985-4993.
31. Scherr, M.; Rossi, J. J.; Sczakiel, G.; Patzel, V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 2000, 28, 2455-2461.
32. Fedor, M. J.; Uhlenbeck, O. C. Substrate sequence effects on "hammerhead" RNA catalytic efficiency. Proc. Natl. Acad. Sci. USA 1990, 87, 1668-1672.
33. Fedor, M. J.; Uhlenbeck, O. C. Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry 1992, 31, 12042-12054.
34. Kitajima, I.; Hanyu, N.; Soejima, Y.; Hirano, R.; Arahira, S.; Yamaoka, S.; Yamada, R.; Maruyama, I.; Kaneda, Y. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan HVJ)-cationic liposomes. Application for ribozymes that target human T-cell leukemia virus type I Tat/Rex mRNA. J. Biol. Chem. 1997, 272, 27099-27106.
35. Usman, N.; Blatt, L. M. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 2000, 106, 1197-1202.
36. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1999, 1489, 69-84.
37. Aigner, A.; Fischer, D.; Merdan, T.; Brus, C.; Kissel, T.; Czubayko, F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 2002, 9, 1700-1707.
38. Pennati, M.; Binda, M.; Colella, G.; Zoppe, M.; Folini, M.; Vignati, S.; Valentini, A.; Citti, L.; De Cesare, M.; Pratesi, G.; Giacca, M.; Daidone, M. G.; Zaffaroni, N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004, 23, 386-394.
39. Tong, A. W.; Zhang, Y. A.; Cunningham, C.; Maples, P.; Nemunaitis, J. Potential clinical application of antioncogene ribozymes for human lung cancer. Clin. Lung Cancer. 2001, 2, 220-226.
40. LaVail, M. M.; Yasumura, D.; Matthes, M. T.; Drenser, K. A.; Flannery, J. G.; Lewin, A. S.; Hauswirth, W. W. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 11488-11493.
41. Kunke, D.; Grimm, D.; Denger, S.; Kreuzer, J.; Delius, H.; Komitowski, D.; Kleinschmidt, J. A. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther. 2000, 7, 766-777.
42. Amado, R. G.; Chen, I. S. Lentiviral vectors - the promise of gene therapy within reach? Science. 1999, 285, 674-676.
43. Miller, A. D. Nonviral liposomes. Methods Mol. Med. 2004, 90, 107-137
44. Cloninger, M. J. Biological applications of dendrimers, Curr. Opin. Chem. Biol. 2002, 6, 742-748.
45. Geiduschek, E. P.; Tocchini-Valentini, G. P. Transcription by RNA polymerase III. Annu. Rev. Biochem. 1988, 57, 873-914.
46. Cotton, M.; Birnstiel, M. L. Ribozyme mediated destruction of RNA in vivo. EMBO J. 1989, 8, 3881-3886.
47. Sano, M.; Taira, K. Ribozyme expression systems. Methods Mol. Biol. 2004, 252, 195-207.
48. Kawasaki, H.; Warashina, M.; Kuwabara, T.; Taira, K. Helicase-attached novel hybrid Ribozymes. Methods Mol. Biol. 2004, 252, 237-243.
49. Macpherson, J. L.; Ely, J. A.; Sun, L. Q.; Symonds, G. P. Ribozymes in gene therapy of HIV-1. Front Biosci. 1999, 4, 497-505.
50. Rossi, J. J. Ribozyme therapy for HIV infection. Adv. Drug Deliv. Rev. 2000, 44, 71-78.
51. Puerta-Fernandez, E.; Barroso-del Jesus, A.; Romero-Lopez, C.; Tapia, N.; Martinez, M. A.; Berzal-Herranz, A. Inhibition of HIV-1 replication by RNA targeted against the LTR region. AIDS. 2005, 19, 863-870.
52. Bramlage, B.; Luzi, E.; Eckstein, F. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Nucleic Acids Res. 2000, 28, 4059-4067.
53. Yu, M.; Ojwang, J.; Yamada, O.; Hampel, A.; Rapapport, J.; Looney, D.; Wong-Staal, F. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1993, 90, 6340-6344.
54. Hotchkiss, G.; Maijgren-Steffensson, C.; Ahrlund-Richter, L. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Mol. Ther. 2004, 10, 172-180.
55. Yamada, O.; Yu, M.; Yee, J. K.; Kraus, G.; Looney, D.; Wong-Staal, F. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther. 1994, 1, 38-45.
56. Michienzi, A.; Cagnon, L.; Bahner, I.; Rossi, J. J. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Sci. USA 2000, 97, 8955-8960.
57. Harrison, G. P.; Lever, A. M. The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure. J. Virol. 1992, 66, 4144-4153.
58. Sun, L. Q.; Warrilow, D.; Wang, L.; Witherington, C.; Macpherson, J.; Symonds, G. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc. Natl. Acad. Sci. USA 1994, 91, 9715-9719.
59. Jackson, W. H. Jr.; Moscoso, H.; Nechtman, J. F.; Galileo, D. S.; Garver, F. A.; Lanclos, K. D. Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme. Biochem. Biophys. Res. Commun. 1998, 245, 81-84.
60. Sun, L. Q.; Pyati, J.; Smythe, J.; Wang, L.; Macpherson, J.; Gerlach, W.; Symonds, G. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs Proc. Natl. Acad. Sci. USA 1995, 92, 7272-7276.
61. Sun, L. Q.; Wang, L.; Gerlach, W. L.; Symonds, G. Target sequence specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. 1995, 23, 2909-2913.
62. Wang, L.; Witherington, C.; King, A.; Gerlach, W. L.; Carr, A; Penny, R.; Cooper, D.; Symonds, G.; Sun, L. Q. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum. Gene Ther. 1998, 9, 1283-1291.
63. + T-lymphocytes in HIV-infected patients. J. Gene Med. 2005, 7, 552-564.
64. Ngok, F. K.; Mitsuyasu, R. T.; Macpherson, J. L.; Boyd, M. P.; Symonds, G. P.; Amado, R. G. Clinical gene therapy research utilizing ribozymes. Methods Mol. Biol. 2004, 252, 581-598.
65. Sierra, S.; Kupfer, B.; Kaiser, R.; Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 2005, 34, 233-244.
66. Duan, L.; Zhu, M.; Ozaki, I.; Zhang, H.; Wei, D. L.; Pomerantz, R. J. Intracellular inhibition of HIV-1 replication using a dual protein-and RNA-based strategy. Gene Ther. 1997, 4, 533-543.
67. Zhou, C.; Bahner, I. C.; Larson, G. P.; Zaia, J. A.; Rossi, J. J.; Kohn, D. B. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994, 149, 33-39.
68. + Cells From HIV-1 - Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes. Blood 1997, 89, 2259-2267.
69. Bai, J.; Banda. N.; Lee, N. S.; Rossi, J.; Akkina, R. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther. 2002, 6, 770-782.
70. Michienzi, A.; Prislei, S.; Bozzoni, I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1996, 93, 7219-7224.
71. Chen, C. J.; Banerjea, A. C.; Harmison, G. G.; Haglund, K.; Schubert, M. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 1992, 20, 4581-4589.
72. Ramezani, A.; Ding, S. F.; Joshi, S. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther. 1997, 4, 861-867.
73. Li, M. J.; Bauer, G.; Michienzi, A.; Yee, J. K.; Lee, N. S.; Kim, J.; Li, S.; Castanotto, D.; Zaia, J.; Rossi, J. J. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 2003, 8, 196-206.
74. O'Brien, S. J.; Moore, J. P. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 2000, 177, 99-111.
75. Qureshi, A.; Zheng, R.; Parlett, T.; Shi, X.; Balaraman, P.; Cheloufi, S.; Murphy, B.; Guntermann, C.; Eagles, P. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem. J. 2006, 394, 511-518.
76. Li, M. J.; Kim, J.; Li, S.; Zaia, J.; Yee, J. K.; Anderson, J.; Akkina, R.; Rossi, J. J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12, 900-909.
77. Cordelier, P.; Kulkowsky, J. W.; Ko, C.; Matskevitch, A. A.; McKee, H. J.; Rossi, J. J.;, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther. 2004, 11, 1627-1637.
78. Luis Abad, J.; Gonzalez, M. A.; del Real, G.; Mira, E.; Manes, S.; Serrano, F.; Bernad, A. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol. Ther. 2003, 8, 475-484.
79. Li, M. J.; Bauer, G.; Michienzi, A.; Yee, J. K.; Lee, N. S.; Kim, J.; Li, S.; Castanotto, D.; Zaia, J.; Rossi, J. J. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 2003, 8, 196-206.
80. Feng, Y.; Leavitt M, Tritz R.; Duarte E.; Kang D.; Mamounas M.; Gilles P.; Wong-Staal F.; Kennedy S.; Merson J.; Yu M.; Barber J. R. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 2000, 276, 271-278.
81. Peracchi, A. Prospects for antiviral ribozymes and deoxyribozymes. Rev. Med. Virol. 2004, 14, 47-64.
82. Bukh, J.; Purcell, R. H.; Miller, R. H. Sequence analysis of the 50 noncoding region of hepatitis C virus. Proc. Natl. Acad. Sci. USA 1992, 89, 4942-4946.
83. Romero-Lopez, C.; Barroso-del Jesus, A.; Puerta-Fernandez, E.; Berzal-Herranz, A. Interfering with hepatitis C virus IRES activity using RNA molecules identified by a novel in vitro selection method. Biol. Chem. 2005, 386, 183-190.
84. Welch, P. J.; Tritz, R.; Yei, S.; Leavitt, M.; Yu, M.; Barber, J. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther. 1996, 3, 994-1001.
85. Sakamoto, N.; Wu, C. H.; Wu, G. Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Invest. 1996, 98, 2720-2728.
86. Macejak, D. G.; Jensen, K. L.; Pavco, P. A.; Phipps, K. M.; Heinz, B. A.; Colacino, J. M.; Blatt, L. M. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. J. Viral Hepat. 2001, 8, 400-405.
87. Jarczak, D.; Korf, M.; Beger, C.; Manns, M. P.; Kruger, M. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons. FEBS J. 2005, 272, 5910-5922.
88. Usman, N.; Blatt, L. M. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 2000, 106, 1197-1202.
89. Li, X.; Kuang, E.; Dai, W.; Zhou, B.; Yang, F. Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus. Virus Res. 2005, 114, 126-132.
90. Nash, K. L.; Alexander, G. J.; Lever, A. M. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J. Viral Hepat. 2005, 12, 346-356.
91. Morrissey, D. V.; Lee, P. A.; Johnson, D. A.; Overly, S. L.; McSwiggen, J. A.; Beigelman, L.; Mokler, V. R.; Maloney, L.; Vargeese, C.; Bowman, K.; O'Brien, J. T.; Shaffer, C. S.; Conrad, A.; Schmid, P.; Morrey, J. D.; Macejak, D. G.; Pavco, P. A.; Blatt, L. M. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. J. Viral Hepat. 2002, 9, 411-418.
92. Feng, Y.; Kong, Y. Y.; Wang, Y.; Qi, G. R. Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biol. Chem. 2001, 382, 655-660.
93. Feng, Y.; Kong, Y. Y.; Wang, Y.; Qi, G. R Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J. Gastroenterol Hepatol. 2001, 16, 1125-1130.
94. Welch, P. J.; Tritz, R.; Yei, S.; Barber, J.; Yu, M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther. 1997, 4, 736-743.
95. Lazarev, V. N.; Shmarov, M. M.; Zakhartchouk, A. N.; Yurov, G. K.; Misurina, O. U.; Akopian, T. A.; Grinenko, N. F.; Grodnitskaya, N. G.; Kaverin, N. V.; Naroditsky, B. S. Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res. 1999, 42, 47-57.
96. Xing, Z.; Whitton, J. L. An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield. J. Virol. 1993, 67, 1840-1847.
97. Albuquerque-Silva, J.; Milican, F.; Bollen, A.; Houard, S. Ribozyme-mediated decrease in mumps virus nucleocapsid mRNA level and progeny in infected vero cells. Antisense Nucleic Acid Drug Dev. 1999, 9, 279-288.
98. Seyhan, A. A.; Vitiello, D.; Shields, M. T.; Burke, J. M. Ribozyme inhibition of alphavirus replication. J. Biol. Chem. 2002, 277, 25957-25962.
99. Cantor, G. H.; McElwain, T. F.; Birkebak, T. A.; Palmer, G. H. Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression. Proc. Natl. Acad Sci. USA 1993, 90, 10932-10936.
100. Tokunaga, T.; Tsuchida, T.; Kijima, H.; Okamoto, K.; Oshika, Y.; Sawa, N.; Ohnishi, Y.; Yamazaki, H.; Miura, S.; Ueyama, Y.; Nakamura, M. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br. J. Cancer. 2000, 83, 833-839.
101. Zhang, Y. A.; Nemunaitis, J.; Tong, A. W. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Mol. Biotechnol. 2000, 15, 39-49.
102. Tsuchida, T.; Kijima, H.; Oshika, Y.; Tokunaga, T.; Abe, Y.; Yamazaki, H.; Tamaoki, N.; Ueyama, Y.; Scanlon, K. J.; Nakamura, M. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 1998, 253, 368-373.
103. Feng, M.; Cabrera, G.; Deshane, J.; Scanlon, K. J.; Curiel, D. T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995, 55, 2024-2028.
104. Wang, C. H.; Tsai, L. J.; Tsao, Y. P.; Hsieh, J. T.; Chien, W. W.; Liao, C. L.; Wang, H, W.; Liu, H. S.; Chen, S. L. Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways. Biochem. Biophys. Rev. Commun. 2002, 298, 805-814.
105. Scherr, M.; Maurer, AB.; Klein, S.; Ganser, A.; Engels, J. W.; Grez, M. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Ther. 1998, 5, 1227-1234.
106. Juhl, H.; Downing, S. G.; Wellstein, A.; Czubayko, F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/ neu by ribozyme targeting. J. Biol. Chem. 1997, 272, 29482-29486.
107. Lui, V. W.; He, Y.; Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. 2001, 3, 169-177.
108. Suzuki, T.; Anderegg, B.; Ohkawa T.; Irie A.; Engebraaten, O.; Halks-Miller, M.; Holm, P. S.; Curiel, D. T.; Kashani-Sabet, M.; Scanlon, K. J. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther. 2000, 7, 241-248.
109. Irie, A.; Matsumoto, K.; Anderegg, B.; Kuruma, H.; Kashani-Sabet, M.; Scanlon, K. J.; Uchida, T.; Baba, S. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Cancer Gene Ther. 2006, 13, 298-305.
110. Bi, F.; Fan, D.; Hui, H.; Wang, C.; Zhang, X. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme. Cancer Gene Ther. 2001, 8, 835-842.
111. Thybusch-Bernhardt, A.; Aigner, A.; Beckmann, S.; Czubayko, F.; Juhl, H. Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo. Eur. J. Cancer. 2001, 37, 1688-1694.
112. Zheng, Y.; Zhang, J.; Rao, Z. Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy. Cancer Biol. Ther. 2004, 3, 1129-1134
113. Kim, Y.; Cairns, M. J.; Marouga, R.; Sun, L. Q. E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes. Cancer Gene Ther. 2003, 10, 707-716.
114. Alvarez-Salas, L. M.; Cullinan, A. E.; Siwkowski, A.; Hampel, A.; DiPaolo, J. A. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl. Acad. Sci. USA 1998, 95, 1189-1194.
115. Kunke, D.; Grimm, D.; Denger, S.; Kreuzer, J.; Delius, H.; Komitowski, D.; Kleinschmidt, J. A. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther. 2000, 7, 766-777.
116. Weng, D.E.; Masci, P. A.; Radka, S. F.; Jackson, T. E.; Weiss, P. A.; Ganapathi, R.; Elson, P. J.; Capra, W. B.; Parker, V. P.; Lockridge, J. A.; Cowens, J. W.; Usman, N.; Borden, E. C. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. 2005, 4, 948-955.
117. Kobayashi, H.; Eckhardt, S. G.; Lockridge, J. A.; Rothenberg, M. L.; Sandler, A. B.; O'Bryant, C. L.; Cooper, W.; Holden, S. N.; Aitchison, R. D.; Usman, N.; Wolin, M.; Basche, M. L. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME).; an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2005, 56, 329-336.
118. Folini, M.; Colella, G.; Villa, R.; Lualdi, S.; Daidone, M. G.; Zaffaroni, N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J. Invest. Dermatol. 2000, 114, 259-267.
119. Yokoyama, Y.; Takahashi, Y.; Shinohara, A.; Wan, X.; Takahashi, S.; Niwa, K.; Tamaya, T. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun. 2000, 273, 316-321.
120. Ludwig, A.; Saretzki, G.; Holm, P. S.; Tiemann, F.; Lorenz, M.; Emrich, T.; Harley, C. B.; von Zglinicki, T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 2001, 61, 3053-3061.
121. Yeo, M.; Rha, S. Y.; Jeung. H. C.; Hu, S. X.; Yang, S. H.; Kim, Y. S.; An, S. W.; Chung, H. C. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int. J. Cancer 2005, 114, 484-489.
122. Hao, Z. M.; Luo, J. Y.; Cheng, J.; Li, L.; He, D.; Wang, Q. Y.; Yang, G. X. Intensive Inhibition of hTERT Expression by a Ribozyme Induces Rapid Apoptosis of Cancer Cells. Cancer Biol. Ther. 2005, 4, 1098-1103.
123. Nosrati, M.; Li, S.; Bagheri, S.; Ginzinger, D.; Blackburn, E. H.; Debs. R. J.; Kashani-Sabet, M. Antitumor activity of systemically delivered ribozymes targeting routine telomerase RNA. Clin. Cancer Res. 2004, 10, 4983-4990.
124. Folini, M.; De Marco, C.; Orlandi, L.; Daidone, M. G.; Zaffaroni, N. Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur. J. Cancer 2000, 36, 2137-2145.
125. Li, Q. X.; Robbins, J. M.; Welch, P. J.; Wong-Staal, F.; Barber, J. R. A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation. Nucleic Acids Res. 2000, 28, 2605-2612.
126. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156-1166.
127. Daly, C.; Coyle, S.; McBride, S.; O'Driscoll, L.; Daly, N.; Scanlon, K.; Clynes, M. mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines. Cytotechnology 1996, 19, 199-205.
128. Gao, Z.; Gao, Z.; Fields, J. Z.; Boman, B. M. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells. Int. J. Cancer 1999, 82, 346-352.
129. Nagata, J.; Kijima, H.; Hatanaka, H.; Asai, S.; Miyachi, H.; Abe, Y.; Yamazaki, H.; Nakamura, M.; Watanabe, N.; Mine, T.; Kondo, T.; Scanlon, K. J.; Ueyama, Y. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int. J. Oncol. 2002, 21, 1021-1026.
130. Wang, F. S.; Kobayashi, H.; Liang, K. W.; Holland, J. F.; Ohnuma, T. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum. Gene Ther. 1999, 10, 1185-1195.
131. Huesker, M.; Folmer, Y.; Schneider, M.; Fulda, C.; Blum, H. E.; Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology 2002, 36, 874-884.
132. Kowalski, P.; Farley, K. M.; Lage, H.; Schneider, E. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Res. 2004, 24, 2231-2235.
133. Kowalski, P.; Stein, U.; Scheffer, G. L.; Lage, H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 2002, 9, 579-586
134. Osada, H.; Tokunaga, T.; Abe, Y.; Asai, S.; Miyachi, H.; Hatanaka, H.; Tsugu, A.; Kijima, H.; Yamazaki, H.; Shima, K.; Ueyama, Y.; Osamura, Y.; Nakamura, M. Reversal of drug resistance mediated by hammerhead ribozyme against multidrug resistance-associated protein 1 in a human glioma cell line. Int. J. Oncol. 2003, 22, 823-827.
135. Materna, V.; Liedert, B.; Thomale, J.; Lage, H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 2005, 115, 393-402.
136. Kowalski, P.; Surowiak, P.; Lage, H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/Pgp, MRP2, and BCRP. Mol. Ther. 2005, 11, 508-522.
137. Mariani, L.; Citti, L.; Nevischi, S.; Eckstein, F.; Rainaldi, G. Ribozyme and free alkylated base: a dual approach for sensitizing Mex+ cells to the alkylating antineoplastic drug. Cancer Gene Ther. 2000, 7, 905-909.
138. Zhang, Q.; Ohannesian D. W.; Erickson L. C. Hammerhead ribozyme-mediated sensitization of human tumor cells after treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. J. Pharmacol. Exp. Ther. 2004, 309, 506-514.
139. Iida, T.; Kijima, H.; Urata, Y.; Goto, S.; Ihara, Y.; Oka, M.; Kohno, S.; Scanlon, K. J.; Kondo, T. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001, 8, 803-814.
140. Perry, W. L. 3rd; Shepard, R. L.; Sampath, J.; Yaden, B.; Chin, W. W.; Iversen, P. W.; Jin, S.; Lesoon, A.; O'Brien, K. A.; Peek, V. L.; Rolfe, M.; Shyjan, A.; Tighe, M.; Williamson, M.; Krishnan, V.; Moore, R. E.; Dantzig, A. H. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed - a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005, 65, 6593-6600.
141. Pennati, M.; Binda, M.; De Cesare, M.; Pratesi, G.; Folini, M.; Citti, L.; Daidone, M. G.; Zunino, F.; Zaffaroni, N. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004, 25, 1129-1136.
142. Wichert, A.; Stege, A.; Midorikawa, Y.; Holm, P. S.; Lage, H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 2004, 23, 945-955.
143. Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y. J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001, 20, 6597-6606.
144. Dawson, P. A.; Marini, J. C. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res. 2000, 28, 4013-4020.
145. Millington-Ward, S., Allers, C.; Tuohy, G.; Conget, P.; Allen, D.; McMahon, H. P.; Kenna, P. F.; Humphries, P.; Farrar, G. J. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta. Hum. Mol. Genet. 2002, 11, 2201-2206.
146. Smicun, Y.; Kilpatrick, M. W.; Florer, J.; Toudjarska, I.; Wu, G.; Wenstrup, R. J.; Tsipouras, P. Enhanced intracellular availability and survival of hammerhead ribozymes increases target ablation in a cellular model of osteogenesis imperfecta. Gene Ther. 2003, 10, 2005-2012.
147. Toudjarska, I.; Kilpatrick, M. W.; Niu, J.; Wenstrup, R. J.; Tsipouras, P. Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta. Antisense Nucleic Acid Drug Dev. 2001, 11, 341-346.
148. Grassi, G.; Forlino, A.; Marini, J. C. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res. 1997, 25, 3451-3458.
149. Lewin, A. S.; Drenser, K. A.; Hauswirth, W. W.; Nishikawa, S.; Yasumura, D.; Flannery, J. G.; LaVail, M. M. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med. 1998, 4, 967-971.
150. Kilpatrick, M. W.; Phylactou, L. A.;Godfrey, M.; Wu, C. H.; Wu, G. Y.; Tsipouras, P. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum. Mol. Genet. 1996, 5, 1939-1944.
151. Langlois, M. A.; Lee, N. S.; Rossi, J. J.; Puymirat, J. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol. Ther. 2003, 7, 670-680.
152. Alami, R.; Gilman, J. G.; Feng, Y. Q.; Marmorato, A.; Rochlin, I.; Suzuka, S. M.; Fabry, M. E.; Nagel, R. L.; Bouhassira, E. E. Antibeta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia. Blood Cells Mol. Dis. 1999, 25, 110-119.
153. Woodson, S. A., Cech T. R. Reverse Self-splicing of the Tetrahymena Group I Intron: Implication for the Directionality of Splicing and for Intron Transposition. Cell 1989, 57, 335-345.
154. Lehmann, K.; Schmidt, U. Group II Introns: Structure and Catalytic Versatility of Large Natural Ribozymes. Crit. Rev. Biochem. Mol. Biol. 2003, 38, 249-303.
155. Cech, T. R.; Zaug, A. J.; Grabowski, P. J. In vitro Splicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence. Cell 1981, 27, 487-496.
156. Cech, T. R. Self-Splicing of Group I Introns. Annu. Rev. Biochem. 1990, 59, 543-568.
157. Cech, T. R. Structure and Mechanism of the Large Catalytic RNAs: Group I and Group II Introns and Ribonuclease P. In: The RNA World, pp. Gesteland R.F. and Atkins J.F., Eds., Cold Spring Harbor Press. 1993, pp. 239-269.
158. Puerta-Fernandez, E.; Romero-Lopez, C.; Barroso-del Jesus, A.; Beizal-Herranz, A. Ribozymes: Recent Advances in the Development of RNA Tools. FEMS Microbiol. Rev. 2003, 27, 75-97.
159. Flor, P. J.; Flanegan, J. B.; Cech, T. R. A Conserved Base Pair within Helix P4 of the Tetahymena Ribozyme Helps to form the Tertiary Structure Required for Self-Splicing. EMBO J. 1989, 8, 3391-3399.
160. 2+ Binding in the Group I Intron Core. J. Mol. Biol. 2003, 329, 229-238.
161. Sullenger, B. A.; Cech, T. R. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1994, 371, 619-622.
162. Jones, J. T.; Lee, S. W.; Sullenger, B. A. Tagging Ribozyme Reaction Sites to Follow trans-splicing in Mammalian Cells. Nature Med. 1996, 2, 643-648.
163. Zarrinkar, P. P.; Sullenger, B.A. Optimizing the Substrate Specificity of a Group I Intron Ribozyme. Biochemistry 1999, 38, 3426-3432.
164. Watanabe, T.; Sullenger, B. A. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl. Acad Sci. USA 2000, 97, 8490-8494.
165. Lan, N.; Howrey, R. P.; Lee, S. W., Smith, C. A.; Sullenger, B. A. Ribozyme-mediated Repair of Sickle β-globin mRNAs in Erythrocyte Precursors. Science 1998, 280, 1593-1596.
166. Lan, N.; Rooney, B. L.; Lee, S. W.; Howery, R. P.; Smith, C. A.; Sullenger, B. A. Enhancing RNA Repair Efficiency by Combining trans-splicing Ribozymes that Recognize Different Accessible Sites on a Target RNA. Mol. Ther. 2000, 2, 245-255.
167. Byun, J.; Lan, N.; Long, M.; Sullenger, B. A. Efficient and Specific Repair of Sickle Beta-globin RNA by trans-splicing Ribozymes. RNA 2003, 9, 1254-1263.
168. Phylactou, L. A., Darrah, C.; Wood, M. J. A. Ribozyme-mediated trans-splicing of a Trinucleotide Repeat. Nat. Genetics 1998, 18, 378-381.
169. Phylactou, L. A. Repair of Myotonic Dystrophy Protein Kinase (DMPK) Transcripts by trans-splicing Ribozymes. Methods Mol. Biol. 2004, 252, 373-383.
170. Bonen, L.; Vogel, J. The Ins and Outs of Group II introns. Trends Genet. 2001, 17, 322-331.
171. Koch, J. L.; Boulanger, S. C., Did-Hajj, S. D.; Hebbar, S. K.; Perlman, P. S. Group II Introns Deleted for Multiple Substructures Retain Self-splicing Activity. Mol. Cell Biol. 1992, 12, 1950-1958.
172. Michel, F.; Umesono, K.; Ozeki, H. Comparative and Functional Anatomy of Group II Catalytic Introns-a Review. Gene 1989, 82, 5-30.
173. Pyle, A. M. Ribozymes: A Distinct Class of metalloenzymes. Science 1993, 261, 709-714.
174. Pyle, A. M. Metal ions in the structure and function of RNA. J. Biol. Inorg. Chem. 2002, 7, 679-690.
175. Guo, H.; Karberg, M.; Long, M.; Jones III, J. P.; Sullenger, B. A.; Lambowitz, A. M. Group II introns designed to insert into therapeutically relevant DNA target site in human cells. Science 2000, 289, 452-457.
176. Karberg, M.; Guo, H.; Zhong, J.; Coon, R.; Perutka, J.; Lambowitz, A. M. Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. Nat. Biotechnol. 2001, 19, 1162-1167.
177. Jones III, J. P.; Kierlin, M. N.; Coon, R.; Perutka, J.; Lambowitz, A. M.; Sullenger, B. A. Retargeting mobile Group II introns to repair mutant genes, Mol. Ther. 2005, 11, 687-694.
178. Li, W.; Ding, S. Viral suppressors of RNA silencing. Curr. Opin. Biotechnol. 2001, 12, 150-154.
179. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411, 494-498.
180. Elbashir, S. M.; Lendeckel, W.; Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15, 188-200.
181. Novina, C.; Sharp, P. The RNAi revolution. Nature 2004, 430, 161-164.
182. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350-353.
183. Uprichard, S. L. The therapeutic potential of RNA interference. FEBS Lett. 2005, 579, 5996-6007.
184. Leung, R. K. M., Whittaker, P. A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Therapeut. 2005, 107, 222-239.
185. Brummelkamp, T. R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2, 243-247.
186. Bertrand, J. Pottier, M.; Vekris, A.; Opolon, P.; Maksimenko, A.; Malvy, C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 2002, 296, 1000-1004.
187. Zhang, Y.; Taylor, M.; Samson, W.; Phillips, M. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Methods Mol. Med. 2005, 106, 11-24.
188. Hall, A. H.; Wan, J.; Shaughnessy, E.E.; Ramsay, S. B.; Alexander, K. A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004, 32, 5991-6000.
189. Allerson, C. R.; Sioufi, N.; Jarres, R.; Prakash, T. P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R.H.; Swayze, E.E.; Bhat, B. Fully 2′ modified oligonucleotide duplex with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 2005, 48, 901-904.
190. Robinson, R. RNAi therapeutics: How likely, how soon? PLos Biol. 2004, 2, 18-20.
191. Bradbury S. RNA interference: new drugs on the horizon. DTT 2005, 10, 1267-1268.
192. Simeoni, F.; Moris, M. C.; Heitz, F.; Divita, G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003, 31, 2717-2724.
193. Paddison, P. J.; Caudy, A. A.; Bernstein, E.; Hannon, G. J.; Conklin, D. S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002, 16, 948-958.
194. Shi, Y. Mammalian RNAi for the masses. Trends Genet. 2003, 19, 9-12.
195. McCaffrey, A. P.; Meuse, L.; Pham, T. T.; Conklin, D. S.; Hannon, G. J.; Kay, M. A. RNA interference in adult mice. Nature 2002, 418, 38-39.
196. Sorensen, D. R.; Leirdal, M.; Sioud, M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003, 327, 761-766.
197. Baker-Herman, T. L.; Fuller, D. D.; Bavis, R. W.; Zabka, A. G.; Golder, F. J.; Doperalski, N. J.; Johnson, R. A.; Waters, J. J.; Mitchell, G. S. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nat. Neurosci. 2004, 7, 48-55.
198. Kishida, T.; Asada, H.; Gojo, S.; Ohashi, S.; Shin-Ya, M.; Yasutomi, K.; Terauchi, R.; Takahashi, K. A.; Kubo, T.; Imanishi, J.; Mazda, O. Sequence specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J. Gene Med. 2004, 6, 105-110.
199. Konishi, Y.; Stegmuller, J.; Matsuda, T.; Bonni, S.; Bonni, A. Cdh1-APC controls axonal growth and patterning in the mammalian brain. Science 2004, 303, 1026-1030.
200. Akaneya, Y.; Jiang, B.; Tsumoto, T. RNAi-induced gene silencing by local electroporation in targeting brain region. J. Neurophysiol. 2005, 93, 594-602.
201. Matsuda, T.; Cepko, C. L. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl. Acad. Sci. 2004, 101, 16-22.
202. Golzio, M.; Mazzolini, L.; Moller, P.; Rols, M. P.; Teissie, J. Inhibition of gene expression in mice muscle by in vivo electrically mediated SiRNA delivery. Gene Ther. 2005, 12, 246-251.
203. Zhang, L.; Nolan, E.; Kreitschitz, S.; Rabussay, D. P. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim. Biophys. Acta 2002, 1572, 1-9.
204. Jiang, M.; Rubbi, C. P.; Milner, J. Gel-based application of SiRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides 2004, 14, 239-248.
205. Zhang, Y.; Boado, R. J.; Pardridge, W. M. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 2003, 5, 1039-1045.
206. Muratovska, A.; Accles, M. R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004, 558, 63-68.
207. Lorenz, C.; Hadwiger, P.; John, M.; Vornlocher, H. P.; Unverzagt, C. Steroid and lipid conjugates of SiRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14, 4975-4977.
208. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H. P. Therapeutic silencing of an endogenous gene by systemic administration of modified SiRNAs. Nature 2004, 432, 173-178.
209. Lois, C.; Refaeli, Y.; Qin, X. F.; Van Parijs, L. Retroviruses as tools to study the immune system. Curr. Opin. Immunol. 2001, 13, 496-504.
210. Rubinson. D. A.; Dillon, C. P.; Kwiatkowski, A. V.; Sievers, C.; Yang, L.; Kopinja, J.; Rooney, D. L.; Ihrig, M. M.; McManus, M. T.; Gertler, F. B.; Scott, M. L.; Van Parijs, L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33, 401-406.
211. Tiscornia, G.; Singer, O.; Ikawa, M.; Verma, I. M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. 2003, 100, 1844-1848.
212. Hill, J. A.; Ichim, T. E.; Kusznieruk, K. P.; Li, M.; Huang, X.; Yan, X.; Zhong, R.; Cairns, E.; Bell, D. A.; Min, W.P. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 2003, 171, 691-696.
213. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N., McIntyre, E.; Radford, I.; Villeval, J. L.; Fraser, C. C.; Cavazzana-Calvo, M.; Fischer, A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255-256.
214. Lenz, G. The RNA interference revolution. Braz. J. Med. Biol. Res. 2005, 38, 1749-1757.
215. Arts, G. J.; Langemeijer, E.; Tissingh, R.; Ma, L.; Pavliska, H.; Dokic, K.; Dooijes, R.; Mesic, E.; Clasen, R.; Michiels, F.; van der Schueren, J.; Lambrecht, M.; Herman, S.; Brys, R.; Thys, K.; Hoffmann, M.; Tomme, P.; van Es, H. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. 2003, 13, 2325-2332.
216. Shen, C.; Buck, A. K.; Liu, X.; Winkler, M.; Reske, S. N. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 2003, 539, 111-114.
217. Zhao, L. J.; Jian, H.; Zhu, H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 2003, 316, 137-141.
218. Hildinger, M.; Auricchio, A. Advances in AAV-mediated gene transfer for the treatment of inherited disorders. Eur. J. Hum. Genet. 2004, 12, 263-271.
219. Kay, M. A.; Nakai, H. Looking into the safety of AAV vectors. Nature 2003, 424, 251.
220. Thomas, C. E.; Ehrhardt, A.; Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4, 346-358.
221. Boden, D.; Pusch, O., Lee, F.; Tucker, L.; Ramratnam, B. Efficient gene transfer of HIV-1-specific short hairpinRNA into human lymphocytic cells using recombinant adeno-associated virus vectors. Mol. Ther. 2004, 9, 396-402.
222. Xia. H.; Mao, Q.; Eliason, S. L.; Harper, S. Q.; Martins, I. H.; Orr, H. T.; Paulson, H. L.; Yang, L.; Kotin, R. M.; Davidson, B. L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 2004, 10, 816-820.
223. Song, E.; Zhu, P.; Lee S. K.; Chowdhury D.; Kussman, S.; Dykxhoorn D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.; Shankar, P.; Marasco, W. A.; Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23, 709-717.
224. Push, O.; Boden, D.; Silbermann, R.; Lee, F.; Tucker, L.; Ramratnam, B. Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Res. 2003, 31, 6444-6449.
225. Zamore, P. D. RNA interference: listening to the sound of silence. Nat. Struct. Biol. 2001, 8, 746-750.
226. Alexopoulou, L.; Holt. A. C.; Medzhitov, R.; Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413, 732-738.
227. Kariko, K.; Bhuyan, P.; Capodici, J.; Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J. Immunol. 2004, 172, 6545-6549.
228. Zuker, M. On folding all suboptimal folding of an RNA molecule. Science 1989, 244, 48-52.
229. Lakatos, L.; Szittya, G.; Silhavy, D.; Burgyan, J. Molecular mechanism of RNA silencing suppression mediated by p19 protein of tombusviruses. EMBO J. 2004, 23, 876-884.
230. Kennedy, S.; Wang, D.; Ruvkun, G. A conserved siRNA degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004, 427, 645-649.
231. McCafrey, A.; Nakai, H.; Pandey, K.; Huang, Z.; Salazar, F.; Xu, H.; Wieland, S.; Marion, P.; Kay, M. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 2003, 21, 639-644.
232. Uprichard, S.; Boyd, B.; Althage, A.; Chisari, F. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. 2005, 102, 773-778.
233. Novina, C. D.; Murray, M. F.; Dykxhoorn, D. M.; Beresford, P. J.; Riess, J.; Lee, S. K.; Collman, R. G.; Lieberman, J.; Shankar, P.; Sharp, P. A. siRNA- directed inhibition of HIV-1 infection. Nat. Med. 2002, 8, 681-686.
234. Qin, X.; An, D.; Chen, I.; Baltimore, D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. 2003, 100, 183-188.
235. Randall, G.; Grakoui, A.; Rice, C. M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad Sci. 2003, 100, 235-240.
236. Yokota, T.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Miyagishi, M.; Maekawa, S.; Yi, L.; Kurosaki, M.; Taira, K.; Watanabe, M.; Mizusawa, H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO J. 2003, 4, 602-608.
237. Ge, Q.; Filip, L.; Bai, A.; Nguyen, T.; Eisen, H.; Chen, J. Inhibition of in.uenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. 2004, 101, 88676-88681.
238. Merl, S.; Michaelis, C.; Jaschke, B.; Vorpahl, M.; Seidl, S.; Wessely, R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 2005, 111, 1583-1592.
239. Ni, B.; Shi, X.; Li, Y.; Gao, W.; Wang, X.; Wu, Y. Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA. Antivir Ther. 2005, 10, 527-533.
240. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Bark, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11, 50-55.
241. Kawasaki, H.; Taira, K. Short hairpin type of dsRNAs that are controlled by tRNA (Val) promoter significantly induce RNAi mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 2003, 31, 700-707.
242. Martinez, L. A.; Naguibneva, I.; Lehrmann, H.; Vervisch, A.; Tchenio, T.; Lozano, G.; Harel-Bellan, A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. 2002, 99, 14849-14854.
243. Choudhury, A.; Charo, J.; Parapuram, S. K.; Hunt, R. C.; Hunt, D. M.; Seliger, B.; Kiessling, R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer 2004, 108, 71-77.
244. Scherr, M.; Battmer, K.; Winkler, T.; Heidenreich, O.; Ganser, A.; Eder, M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003, 101, 1566-1569.
245. Rapozzi, V.; Xodo, L. E. Efficient silencing of bcr/abl oncogene by single- and double-stranded siRNAs targeted against b2a2 transcripts. Biochemistry 2004, 43, 16134-16141.
246. Duxbury, M. S.; Mattes, E.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg. 2004, 240, 667-676.
247. Huang, H.; Cheville, J. C.; Pan, Y.; Roche, P. C.; Schmidt, L. J.; Tindall, D. J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 2001, 276, 38830-38836.
248. Cioca, D.; Aoki, Y.; Kiyosawa, K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. 2003, 10, 125-133.
249. Futami, T.; Miyagishi, M.; Seki, M., Taira, K. Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucleic Acids Res. Suppl. 2002, 2, 251-252.
250. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15-21.
251. Nieth, C.; Priebsch, A.; Stege, A.; Lage, H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003, 545, 144-150.
252. Yague, E.; Higgins, C.; Raguz, S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther. 2004, 11, 1170-1174.
253. Liang, Z.; Yoon, Y.; Votaw, J.; Goodman, M.; Williams, L.; Shim, H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65, 967-971.
254. Takei, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004, 64, 3365-3370.
255. Filleur, S.; Courtin, A.; Ait-Si-Ali, S.; Guglielmi, J.; Merle, C.; Harel-Bellan, A.; Clezardin, P.; Cabon, F. SiRNA mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin- 1 and slows tumor vascularization and growth. Cancer Res. 2003, 63, 3919-3922.
256. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scarial, P. V.; Woodlel, M. C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32, e149.
257. Ding, H.; Schwarz, D. S.; Keene, A.; Affar, E. B.; Fenton, L.; Xia, X.; Shi, Y.; Zamore, P. D.; Xu, Z. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell. 2003, 2, 209-217.
258. Kao, S. C.; Krichevsky, A.; Kosik, K.; Tsai, L. H. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 2003, 279, 1942-1949.
259. Harper, S. Q.; Staber, P. D.; He, X.; Eliason, S. L.; Martins, I. H.; Mao, Q.; Yang, L.; Kotin, R. M.; Paulson, H. L.; Davidson, B. L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. 2005, 102, 5820-5825.
260. Schiffelers, R.; Xu, J.; Storm, G.; Woodle, M.; Scaria, P. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum. 2005, 52, 1314-1318.
261. Crooke, T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1999, 1489, 31-44.
262. Agrawal, S.; Jiang, Z.; Zhao, Q.; Shaw, D.; Cai, Q.; Roskey, A.; Channavajjala, L.; Saxinger, C.; Zhang, R. Mixed-backbone oligonucleotides as second generation antisense oligonulcleotides. In vitro and in vivo studies. Proc. Natl. Acad. Sci. 1997, 94, 2620-2625.
263. Summerton, J.; Weller, D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucl Acid Drug Dev. 1997, 7, 187-195.
264. Stein, C. A.; Subasinghe, C.; Shinozuka, K.; Cohen, J. S. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988, 16, 3209-3221.
265. Guvakova, M. A.; Yakubov, L. A.; Vlodavsky, I,; Tonkinson, J. L.; Stein C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 1995, 270, 2620-2627.
266. Fennewald, S. M.; Rando, R. F. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 1995, 270, 21718-21721.
267. Rockwell, P.; O'Connor, W. J.; King, K.; Goldstein, N. I.; Zhang, L. M.; Stein, C.A. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. 1997, 94, 6523-6528.
268. Lederman, S,; Sullivan, G.; Benimetskaya, L.; Lowy, I.; Land, K.; Khaled, Z.; Cleary, A.M,; Yakubov, L.; Stein, C.A. Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetradformation. Antisense Nucleic Acid Drug Dev. 1996, 6, 281-289.
269. Benimetskaya, L.; Loike, J. D.; Khaled, Z.; Loike, G.; Silverstein, S. C.; Cao, L.; el Khoury, J.; Cai, T. Q.; Stein, C. A. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide- binding protein. Nat. Med. 1997, 3, 414-420.
270. Khaled, Z.; Benimetskaya, L,; Zeltser, R.; Khan, T.; Sharma, H. W.; Narayanan, R.; Stein, C.A. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1996, 24, 737-745.
271. Henry, S. P.; Bolte, H.; Auletta, C.; Kornbrust, D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 1997, 120, 145-155.
272. Henry, S. P.; Giclas, P. C.; Leeds, J.; Pangburn, M.; Auletta, C.; Levin, A. A., Kornbrust, D.J. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 1997, 281, 810-816.
273. Ban, N.; Nissen, P.; Hansen, J.; Moore, P.B.; Steitz, T.A. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 2000, 289, 905-920.
274. Frank, D.N.; Pace, N.R. Ribonuclease P: unity and diversity in a tRNA processing ribozyme. Annu. Rev. Biochem. 1998, 67, 153-180.
275. Schon, A. Ribonuclease P: the diversity of a ubiquitous RNA processing enzyme. FEMS Microbiol. Rev. 1999, 23, 391-406.
276. Hsieh J.; Andrews A.J.; Fierke C.A. Roles of protein subunits in RNA-protein complexes: lessons from ribonuclease P. Biopolymers 2004, 73, 79-89
277. Xiao, S.; Scott, F.; Fierke, C.A. Engelke, D.R. Eukaryotic Ribonuclease P, a plurality of ribonucleoprotein enzymes. Annu. Rev. Biochem. 2002, 71, 165-189.
278. Stathopoulos, C.; Tekos, A.; Zarkadis, I.K.; Drainas, D. Extensive deproteinization of Dictyostelium discoideum RNase P reveals a new catalytic activity. Eur. J. Biochem. 2001, 268, 2134-2140.
279. Gopalan, V.; Vioque, A.; Altman, S. RNase P: variations and uses. J. Biol. Chem. 2002, 277, 6759-6762.
280. Cobaleda, C.; Gutierrez-Cianca, N.; Perez-Losada, J.; Flores, T.; Garcia-Sanz, R.; Gonzalez, M.; Sanchez-Garcia, I. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000, 95, 731-737.
281. Liu, F.; Altman, S. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli. Genes Dev. 1995, 9, 471-480.
282. Trang, P.; Kilani, A.; Kim, J.; Liu, F. A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1. J. Mol. Biol. 2000, 301, 817-826.
283. Trang, P.; Lee, M.; Nepomuceno, E.; Kim, J.; Zhu, H.; Liu, F. Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 5812-5817.
284. Kilani, A.F.; Trang, P.; Jo, S.; Hsu, A.; Kim, J.; Nepomuceno, E.; Liou, K.; Liu, F. RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture. J. Biol. Chem. 2000, 275, 10611-10622.
285. Trang, P.; Lee, J.; Kilani, A.F.; Kim, J.; Liu, F. Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered RNase P ribozyme. Nucleic Acids Res. 2001, 29, 5071-5078.
286. Trang, P.; Hsu, A.; Zhou, T.; Lee, J.; Kilani, A. F.; Nepomuceno, E.; Liu, F. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. J. Mol. Biol. 2002, 315, 573-586.
287. Zou, H.; Lee, J.; Umamoto, S.; Kilani, A. F.; Kim, J.; Trang, P.; Zhou, T.; Liu, F. Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells. J. Biol. Chem. 2003, 278, 37265-37274.
288. Kim, K.; Umamoto, S.; Trang, P.; Hai, R.; Liu, F. Intracellular expression of engineered RNase P ribozymes effectively blocks gene expression and replication of human cytomegalovirus. RNA 2004, 10, 438-447.
289. Ma, M.; Benimetskaya, L.; Lebedeva, I.; Dignam, J.; Takle, G.; Stein, C. A. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. Nat. Biotechnol. 2000, 18, 58-61.
290. Plehn-Dujowich, D.; Altman, S. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc. Natl. Acad. Sci. USA 1998, 95, 7327-7332.
291. Kawa, D.; Wang, J.; Yuan, Y.; Liu, F. Inhibition of viral gene expression by human ribonuclease P. RNA 1998, 4, 1397-1406.
292. Zhou, T.; Kim, J.; Kilani, A. F,; Kim, K.; Dunn, W.; Jo, S.; Nepomuceno, E.; and Liu, F. In vitro selection of external guide sequences for directing RNase P-mediated inhibition of viral gene expression. J. Biol. Chem. 2002, 277, 30112-30120.
293. Li, H.; Trang, P.; Kim, K.; Zhou, T.; Umamoto, S.; Liu, F. Effective inhibition of human cytomegalovirus gene expression and growth by intracellular expression of external guide sequence RNA. RNA 2006, 12, 63-72.
294. Dunn, W.; Trang, P.; Khan, U.; Zhu, J.; Liu, F. RNase P-mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences. Proc. Natl. Acad. Sci. USA 2001, 98, 14831-14836.
295. Zhu, J.; Trang, P.; Kim, K.; Zhou, T.; Deng, H.; Liu, F. Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc. Natl. Acad. Sci. USA 2004, 101, 9073-9078.
296. Hnatyszyn, H.; Spruill, G.; Young, A.; Seivright, R.; Kraus. G. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis. Gene Ther. 2001, 8, 1863-1871.
297. Kraus, G.; Geffin, R.; Spruill, G.; Young, A. K.; Seivright, R.; Cardona, D.; Burzawa, J.; Hnatyszyn, H. J. Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. Proc. Natl. Acad. Sci. USA 2002, 99, 3406-3411.
298. Barnor, J.; Endo, Y.; Habu, Y.; Miyano-Kurosaki, N.; Kitano, M.; Yamamoto, H.; Takadu, H. Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease P. Bioorg. Med. Chem. Lett. 2004, 14, 4941-4944.
299. Dreyfus, D. H.; Matckuk, A.; Fuleihan, R. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA. Int. Immunopharmacol. 2004, 4, 1015-1027.
300. + progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res. Ther. 2004, 1, 1-11.